Reviews

• Acetyl-l-carnitine for dementia (Cochrane Review)
• Antidepressants for treating depression in dementia (Cochrane Review)
• Aroma therapy for dementia (Cochrane Review)
• Aspirin for vascular dementia (Cochrane Review)
• Cholinesterase inhibitors for dementia with Lewy bodies (Cochrane Review)
• Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly (Cochrane Review)
• D-cycloserine for Alzheimer's disease (Cochrane Review)
• Dehydroepiandrosterone (DHEA) supplementation for cognitive function. (Cochrane Review)
• Donepezil for dementia due to Alzheimer's disease (Cochrane Review)
• Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. (Cochrane Review)
• Galantamine for Alzheimer's disease (Cochrane Review)
• Ginkgo Biloba for Cognitive Impairment and Dementia (Cochrane Review)
• Haloperidol for agitation in dementia (Cochrane Review)
• Homeopathy for dementia (Cochrane Review)
• Hormone replacement therapy for cognitive function in postmenopausal women (Cochrane Review)
• Hormone replacement therapy to maintain cognitive function in women with dementia (Cochrane Review)
• Hydergine for dementia (Cochrane Review)
• Ibuprofen for Alzheimer's disease (Cochrane Review)
• Indomethacin for the treatment of Alzheimer's disease patients (Cochrane Review)
• Lecithin for dementia and cognitive impairment (Cochrane Review)
• Memantine for dementia (Cochrane Review)
• Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment (Cochrane Review)
• Nicergoline for dementia and other age associated forms of cognitive impairment (Cochrane Review)
• Nicotine for Alzheimer's disease (Cochrane Review)
• Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review)
• Physostigmine for Alzheimer's disease (Cochrane Review)
• Piracetam for dementia or cognitive impairment (Cochrane Review)
• Propentofylline for Dementia (Cochrane Review)
• Reality orientation for dementia (This review has been withdrawn by the editorial group. Abstract not available)
• Reminiscence therapy for dementia (Cochrane Review)
• Rivastigmine for Alzheimer's disease (Cochrane Review)
• Selegiline for Alzheimer's disease (Cochrane Review)
• Shunting for Normal Pressure Hydrocephalus (NPH) (Cochrane Review)
• Snoezelen for dementia (Cochrane Review)
• Statins for the prevention of Alzheimer's disease (Cochrane Review)
• Subjective barriers to prevent wandering of cognitively impaired people (Cochrane Review)
• Support for carers of people with Alzheimer's type dementia (This review has been withdrawn by the editorial group. Abstract not available)
• Tacrine for Alzheimer's disease (This review has been withdrawn by the editorial group. Abstract not available)
• Thiamine for Alzheimer's disease (Cochrane Review)
• Thioridazine for dementia (Cochrane Review)
• Transcutaneous Electrical Nerve Stimulation (TENS) for dementia (Cochrane Review)
• Validation therapy for dementia (Cochrane Review)
• Vinpocetine for cognitive impairment and dementia (Cochrane Review)
• Vitamin B12 for cognition (Cochrane Review)
• Vitamin E for Alzheimer's disease (Cochrane Review)

Protocols

• Alpha lipoic acid for dementia (Cochrane Protocol)
• Cerebrolysin for Alzheimer's disease (Cochrane Protocol)
• Cognitive behaviour therapy (CBT) for depressed carers of people with Alzheimer's disease and related disorders (Cochrane Protocol)
• Cognitive rehabilitation interventions to improve memory functioning in early-stage Alzheimer's disease and vascular dementia (Cochrane Protocol)
• Donepezil for vascular cognitive impairment (Cochrane Protocol)
• The effect of cholinesterase inhibitors on the risk of falls and injuries in patients with mild to moderate Alzheimer's dementia (Cochrane Protocol)
• The effect of vitamin B6 on cognition (Cochrane Protocol)
• The Effectiveness of Atypical Antipsychotics for the Treatment of Agitation and Psychosis in Alzheimer's disease (Cochrane Protocol)
• The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease (Cochrane Protocol)
• Folic Acid with or without vitamin B12 for cognition and dementia. (Cochrane Protocol)
• Idebenone for Alzheimer's disease (Cochrane Protocol)
• Light Therapy for Managing Sleep, Behaviour, and Mood Disturbances Associated with Alzheimer Disease (Cochrane Protocol)
• Melatonin for cognitive impairment (Cochrane Protocol)
• Metrifonate for Alzheimer's disease (Cochrane Protocol)
• Music therapy in the care of people with dementia (Cochrane Protocol)
• Naftidrofuryl for cognitive impairment (Cochrane Protocol)
• Pentoxifylline for dementia (Cochrane Protocol)
• Pharmacological interventions for sleep disorder in people with dementia (Cochrane Protocol)
• Respite care for people with dementia (Cochrane Protocol)
• Tacrine for Alzheimer's disease (individual patient data) (Cochrane Protocol)
• Thiamine for Wernicke-Korsakoff Syndrome in people at risk from over-consumption of alcohol (Cochrane Protocol)
• Use of validated rating scales for behavioural problems in dementia (Cochrane Protocol)
• Valproic acid for agitation in dementia (Cochrane Protocol)